Phase 2, international, multicenter, randomized, open label and parallel group study to evaluate the efficacy and safety of CC-486 (oral azacitidine) alone and in combination with durvalumab (MEDI4736) in subjects with myelodysplastic syndrome who do not achieve a response objective treatment with injectable azacitidine or decitabine
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: CELGENE INTERNATIONAL II SARL
- Phase: II
- Execution start: 07/06/2016
- End of execution: 30/08/2019
- PI: FRANCISCA HERNANDEZ MOHEDO